Keyword: Bind Therapeutics
Ahead of Fierce 15 2019, we look back at how former winners are getting on.
Bind rose to prominence on the strength of its pedigree and venture backing as much as its technology. But its nanotechnology platform came up short, leaving the company to seek a Big Pharma partner to stay afloat. No one came to the rescue, and Bind sold off its assets to Pfizer for $40 million.
Bind Therapeutics had the dubious honor of being one of only a handful of biotechs to file for bankruptcy last year. After a series of trial failures, dropped deals and major staff cuts, Bind went into Chapter 11, and its assets were sold off to Pfizer for just $40 million.
Welcome to our new annual feature that aims to name and shame those biopharmas and medical device companies that made an attempt at being ripe but turned out to be rotten.
Microcap Cerulean Pharma is to cut 48% of its workforce as it reels from this week’s failed Phase II combo study with its lead candidate CRLX101.
A snapshot survey of biotech chiefs during the second quarter has shown that their confidence to be able to raise funds has doubled since Q1, but they are a little shakier on deals and partnerships.
The Robert Langer-backed nanoparticle cancer biotech Bind, after a decade in the business, looks to be at the end of the road after the company said it was seeking an approval for a “stalking horse” bid today from Pfizer.
After a strong year with a string of deals and successful funding rounds to its name, Nanoparticle specialist Selecta Biosciences has filed for a $75 million initial public offering.
Bind signs a research deal with Affilogic, but the collab won't help its precarious financial situation.
Two biotech companies, Bind Therapeutics and NephroGenex, are seeking the temporary protection of a Chapter 11 bankruptcy order as both look to a potential sale.